Diversity in Medicine: Are There Racial Differences in Treatment Out…

Houston Methodist DeBakey Heart and Vascular Center

C. Yancy

Intravenous Iron for Heart Failure: Where Is the Evidence?

28th Annual Heart Failure 2024: An Update on Therapy

I. Pina

Overview of Iron Deficiency in Heart Failure & Recognizing Iron Defi…

ACHL

M. Vaduganathan

Treatment of Iron Deficiency Across the Heart Failure Spectrum

ACHL

S. Gale

Cardiotoxicity in Breast Cancer – Case Discussion

University of Colorado Department of Medicine

L. Kondapalli

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Cardio-Oncology: Definitions and Scope

University of Colorado Department of Medicine

L. Kondapalli

How to Minimize and Manage Checkpoint Inhibitors Adverse Cardiac Eve…

University of Colorado Department of Medicine

L. Kondapalli

The PRONOUNCE and HERO Trials: The Cardiovascular Safety of Degareli…

Przemyslaw Twardowski

2023 Update on Cardiac Amyloid

MUSC Cardiology

J. Griffin

How the Experts Manage: Cardiotoxicity and IO in NSCLC

MI&T Congressi

J. Remon Masip

ACC 2024 Insights: Pearls of Cardio-Oncology Screening and Management

ACC 2024 Insights

J. Johnson

ADT for Prostate Cancer and Cardiovascular Health Considerations

Andrew Hahn

Cardio-Oncology in Breast Cancer: Treatment Options for Anthracyclin…

Total Health

I. Rhea

Cardiotoxicity in Melanoma – Case Discussion

University of Colorado Department of Medicine

L. Kondapalli

Cardiotoxicity in RCC – Case Discussion

University of Colorado Department of Medicine

L. Kondapalli

Iron Deficiency Cases and Panel Discussions

ACHL

A. Mardis, S. Gale, M. Vaduganathan

Cardiac Disease in Breast Cancer: Background & Risk Factors

Total Health

I. Rhea

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

Monia Marchetti

Updates on Cardiac Amyloidosis: A “Rare” Disease Hiding in Plain Sig…

Courage and Innovation Symposium: Heart Failure & Heart Transplantation

N. Sarswat